-
2022 ASCO GU First Look at AI Power!
Time of Update: 2022-03-06
Here, we conducted the first training and validation of predictive biomarkers for the use of ADT in localized prostate cancer through multiple phase III NRG Society of Oncology randomized trials .
-
Molecular Cancer Zhang Jing/Zhu Jinshui of Shanghai Jiaotong University discover potential therapeutic targets for gastric cancer
Time of Update: 2022-03-06
On February 14, 2022, Shanghai Jiaotong University Zhang Jing and Zhu Jinshui published a joint communication online in Molecular Cancer (IF=27) entitled "METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p /AKT1S1 axis”, which found that METTL14 was downregulated in GC tissue samples and that its low expression was a prognostic factor for poor survival in GC patients .
-
Case Sharing Prof. Baoli: Facing Difficulties, Selinexor Lights the Light of Hope for MM Patients After Multi-line Relapse
Time of Update: 2022-03-06
Selinexor (ATG-010), as the world's first approved oral selective inhibitor of nuclear export protein (SINE), targets a new tumor treatment mechanism and inhibits nuclear export protein 1 (SINE) in a slow and reversible manner ( XPO1), induces tumor cell apoptosis, and exhibits good anti-MM activity in clinical trials .
-
Molecular Cancer Wang Fubing's team from Zhongnan Hospital of Wuhan University: Engineered exosomes as dendritic cell in situ vaccines enhance anti-tumor immunity of breast cancer
Time of Update: 2022-03-06
On February 11, 2022, Wang Fubing, Zhongnan Hospital of Wuhan University, and Yuan Chunhui's team of Wuhan Women and Children's Health Care Center published online at Molecular Cancer (IF=27) entitled "Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer”, which loaded the immunogenic cell death (ICD) inducers human neutrophil elastase (ELANE) and Hiltonol (a TLR3 agonist) into engineered α-lactalbumin (α-LA) breast cancer-derived exosomes to form an in situ DC vaccine (HELA-Exos) .
-
One is listed in JCO, the other is pancreatic cancer, these two KARS inhibitors are worth paying attention to tumor intelligence
Time of Update: 2022-03-06
(If you want the original text of the document, you can add Xiaobian WeChat yxj_oncology to get it) Key points J Clin Oncol: Another new KRASG12C inhibitor shows considerable efficacy in solid tumors BLOOD: New CAR-T product shows safety in primary CNS lymphoma New Drug: Novel KRASG12C Inhibitor Shows High Disease Control Rate in Advanced Pancreatic Cancer New Drug: Novel c-MET Inhibitor Approved in China Adagrasib (MRTX849) is an oral, highly selective, small molecule KRASG12C inhibitor .
-
This fruit was found to enhance anti-tumor effects, overcome PD-1 resistance through gut flora
Time of Update: 2022-03-06
Results showed increased tumor growth in mice treated with CC and anti-CD8+ monoclonal antibody compared to CC/IsoCD8+ (control), suggesting that the microbiome-mediated effects of CC are CD8+ T cell-dependent .
-
High-grade non-muscle invasive bladder cancer new weapon: N-803+ BCG bladder retention rate of 92% 2022 ASCO GU
Time of Update: 2022-03-06
032 is an open-label, multicenter Phase 3 study to investigate the efficacy of intravesical infusion of BCG + N-803 in BCG-unresponsive high-grade NMIBC carcinoma in situ (CIS) cohorts and papillary lesions .
The primary endpoints for the papillary lesion cohort and the CIS cohort were 12-month disease-free survival and complete response (CR) rate, respectively .
-
How to deal with vomiting after using ALK-TKI?
Time of Update: 2022-03-06
What degree of vomiting needs to be dealt with?
Starting from the Southwest Expert Advice on Adverse Reactions of ALK-TKI (2021 Edition), Track the Evidence of Evidence-Based Medicine!
Pay attention to the "Guide time is up" column of the "Medical Tumor Channel" video number to learn more dry goods~
-
For the first time in Asia, the personalized tumor vaccine encoding neoantigen mRNA from Sri Lanka entered the overseas clinical stage
Time of Update: 2022-03-06
In a phase I clinical trial in Australia, Sterling will further explore the safety and efficacy of mRNA-encoded neoantigen-encoding mRNA personalized tumor vaccine therapy in patients with advanced malignant solid tumors .
-
Ponatinib plus FLAG-IDA regimen in blast-stage chronic myeloid leukemia (MATCHPOINT): results of a single-arm, multicenter, phase I/II trial
Time of Update: 2022-03-06
Therefore, Mhairi Copland et al designed the MATCHPOINT study to determine the tolerability and optimal dose of ponatinib in combination with the FLAG-IDA regimen in patients with CML-BP .
-
The world's first!
Time of Update: 2022-03-06
February 18, 2022/eMedClub News/--A few days ago, Immune Onco Biomedical Technology Co. , Ltd. announced the successful completion of the world’s first dual-target antibody-receptor recombinant prot
-
Can the combined immune regimen rewrite the diagnosis and treatment of esophageal cancer?
Time of Update: 2022-03-06
The CheckMate 648 study[1] is a phase III, randomized, global clinical study evaluating the efficacy of nivolumab combined with chemotherapy or ipilimumab versus chemotherapy alone in the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma .
-
Systemic drug delivery for solid tumors!
Time of Update: 2022-03-06
February 16, 2022/eMedClub News/--On February 9, 2022, Sirnaomics, a leading biopharmaceutical company focused on the discovery and development of RNAi therapeutics, announced the launch of its small interfering RNA Phase I clinical trial study of (siRNA) candidate STP707 by intravenous systemic administration in the treatment of various solid tumors .
-
Two major CAR-T therapies "topped" NEJM, but one is happy and the other is worried about tumor information
Time of Update: 2022-03-06
In this international phase III trial, patients with relapsed or refractory LBCL within 12 months of first-line chemoimmunotherapy were randomly assigned (1:1) to receive axi-cel or standard therapy (using investigator's choice of , two or three cycles of chemoimmunotherapy, and high-dose chemotherapy and autologous stem cell transplantation for responding patients) .
-
2022 ASCO-GU MAGNITUDE opens a new era of PARPi and NHT
Time of Update: 2022-03-06
The MAGNITUDE trial evaluated whether NIRA combined with abiraterone plus prednisone (AAP) versus AAP could improve outcomes in patients with mCRPC, regardless of the presence or absence of HRR-related gene alterations .
-
Express treatment of pancreatic cancer, Amgen KRAS inhibitor achieves 84% disease control rate
Time of Update: 2022-03-06
▎WuXi AppTec Content Team Editor A few days ago, Amgen announced the latest efficacy and safety results of its KRAS G12C inhibitor, Lumarkras (sotorasib), in the treatment of patients with advanced pancreatic cancer harboring KRAS G12C mutations .
-
Treat Bladder Cancer!
Time of Update: 2022-03-06
February 17, 2022/eMedClub News/--On February 14, 2022, Astellas and Seagen announced their co-developed ADC drug PADCEV® (enfortumab vedotin-ejfv), a single drug Preliminary results from the EV-103 study H cohort in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for cisplatin-based chemotherapy .
-
Cancer patient who has undergone 12 chemotherapy treatments finally won the Winter Olympics gold medal!
Time of Update: 2022-03-06
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platformCarboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28), a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
-
Professor Liu Qiqi's team: The application of dynamic monitoring of MRD in the first remission and treatment of low-risk AML patients and its significance to clinical prognosis
Time of Update: 2022-03-06
According to the different treatment regimens after remission, patients were divided into three groups: chemotherapy group (CMT), auto-HSCT group and allo-HSCT group .
-
Gastroenterology Shanghai Jiaotong University Fang Jingyuan/Chen Yingxuan/Wang Zheng found that these two kinds of bacteria in feces can assist in early diagnosis/screening of gastric cancer
Time of Update: 2022-03-06
On February 12, 2022, Fang Jingyuan, Chen Yingxuan and Wang Zheng of Shanghai Jiaotong University published a joint communication online in Gastroenterology (IF=23) entitled "Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for non-invasive screening and early warning of gastric cancer”, an observational study including 1,043 patients from ten hospitals in China .
